Results 141 to 150 of about 17,227 (165)

Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell Lines. [PDF]

Int J Mol Sci
Sohn SH, Sul HJ, Kim BJ, Zang DY.
europepmc   +1 more source

Transcriptomic Analysis of TDP1-Knockout HEK293A Cells Treated with the TDP1 Inhibitor (Usnic Acid Derivative). [PDF]

Int J Mol Sci
Zakharenko AL, Dyrkheeva NS, Markov AV, Kleshchev MA, Ryabchikova EI, Malakhova AA, Orishchenko KE, Okorokova LS, Shtokalo DN, Medvedev SP, Zakian SM, Tupikin AA, Kabilov MR, Luzina OA, Deyev SM, Lavrik OI.   +15 more
europepmc   +1 more source

Validating TDP1 as an Inhibition Target for Lipophilic Nucleoside Derivative in Human Cells. [PDF]

Int J Mol Sci
Chernyshova IA, Kornienko TE, Dyrkheeva NS, Zakharenko AL, Chepanova AA, Orishchenko KE, Kurochkin NN, Drenichev MS, Lavrik OI.   +8 more
europepmc   +1 more source

Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis. [PDF]

Front Immunol
Zhou J, Ye W, Ranarisoa SN, Tian L.
europepmc   +1 more source

Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study. [PDF]

J Clin Med
Acar O, Agaoglu AB, Sahbazlar M, Ekinci F, Erdogan AP.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer

Cancers, 2023
Agnieszka Slowik, Paweł Potocki, Piotr Wysocki   +2 more
exaly  

PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice

International Journal of Pharmaceutics, 2014
Joseph Balthasar, Dhaval Shāh
exaly  

Prospective trial on topotecan salvage therapy in primary CNS lymphoma

Annals of Oncology, 2006
Peter Martus, Agnieszka Korfel, J Birkmann   +2 more
exaly